Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term adverse effects. Found 222 abstracts

no pagination
Held-Warmkessel J. Targeted cancer. These "smart weapons" hit cancer in novel ways. Nursing. 2008 Sep;38(9):26-32.
Konski A, Garcia M, John M, Krieg R, Pinover W, Myerson R, Willett C. Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08. Int J Radiat Oncol Biol Phys. 2008 Sep;72(1):114-8.   PMCID: PMC2570743
Mehta RS, Chwistek M. Bisphosphonates and osteonecrosis of the jaw #196. J Palliat Med. 2008 Sep;11(7):1039-40.
Morgan MA, Darcy KM, Rose PG, DeGeest K, Bookman MA, Aikins JK, Sill MW, Mannel RS, Allievi C, Egorin MJ, Gynecologic Oncology G. Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group. Gynecol Oncol. 2008 Sep;110(3):329-35.   PMCID: PMC2577579
O'Sullivan MJ, Morrow M. Images in clinical medicine. Blue hives. The New England journal of medicine. 2008 Feb 07;358(6):e6.
Small W, Berlin J, Freedman GM, Lawrence T, Talamonti MS, Mulcahy MF, Chakravarthy AB, Konski AA, Zalupski MM, Philip PA, Kinsella TJ, Merchant NB, Hoffman JP, Benson AB, Nicol S, Xu RM, Gill JF, McGinn CJ. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol. 2008 Feb 20;26(6):942-7.
von Mehren M, Schilder RJ, Cheng JD, Temmer E, Cardoso TM, Renshaw FG, Bayever E, Zannikos P, Yuan Z, Cohen RB. A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies. Ann Oncol. 2008 Oct;19(10):1802-9.   PMCID: PMC2598415
Wirk B, Klumpp TR, Ulicny J, Herman JH, Gajewski JL, Martin ME, Emmons RV, Mangan KF. Lack of effect of donor-recipient Rh mismatch on outcomes after allogeneic hematopoietic stem cell transplantation. Transfusion. 2008 Jan;48(1):163-8.
Chang DT, Feigenberg SJ, Indelicato DJ, Morris CG, Lightsey J, Grobmyer SR, Copeland EM, Mendenhall NP. Long-term outcomes in breast cancer patients with ten or more positive axillary nodes treated with combined-modality therapy: The importance of radiation field selection. International Journal of Radiation Oncology Biology Physics. 2007 Mar;67(4):1043-51.
Haas NB, Uzzo RG. Tyrosine kinase inhibitors and anti-angiogenic therapies in kidney cancer. Current treatment options in oncology. 2007 Jun;8(3):211-26.
Jordan VC. Tamoxifen or raloxifene for breast cancer chemoprevention: a tale of two choices--point. Cancer Epidemiology, Biomarkers and Prevention. 2007 Nov;16(11):2207-9.
Terry MB, Knight JA, Zablotska L, Wang Q, John EM, Andrulis IL, Senie RT, Daly M, Ozcelik H, Briollais L, Santella RM. Alcohol metabolism, alcohol intake, and breast cancer risk: a sister-set analysis using the Breast Cancer Family Registry. Breast Cancer Res Treat. 2007 Dec;106(2):281-8.
Gordon MS, Matei D, Aghajanian C, Matulonis UA, Brewer M, Fleming GF, Hainsworth JD, Garcia AA, Pegram MD, Schilder RJ, Cohn DE, Roman L, Derynck MK, Ng K, Lyons B, Allison DE, Eberhard DA, Pham TQ, Dere RC, Karlan BY. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol. 2006 Sep 10;24(26):4324-32.
Manne S, Lessin S. Prevalence and correlates of sun protection and skin self-examination practices among cutaneous malignant melanoma survivors. J Behav Med. 2006 Oct;29(5):419-34.
Ozols RF, Bookman MA, du Bois A, Pfisterer J, Reuss A, Young RC. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel. Gynecol Oncol. 2006 Oct;103(1):1-6.
Talamonti MS, Small W, Mulcahy MF, Wayne JD, Attaluri V, Colletti LM, Zalupski MM, Hoffman JP, Freedman GM, Kinsella TJ, Philip PA, McGinn CJ. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Annals of Surgical Oncology 13 (2): 150-158 Feb 2006. 2006 Feb;13(2):150-8.
Cortellino S, Turner DP, Bellacosa A. Induction of deoxyribonucleic acid damage by gamma irradiation. Methods Mol Biol. 2004 Jan;285:127-32.
Turner DP, Yeung AT, Bellacosa A. Ultraviolet irradiation of cells. Methods Mol Biol. 2004 Jan;285:133-7.
Bellacosa A, Moss EG. RNA repair: damage control. Curr Biol. 2003 Jun 17;13(12):R482-4.
Chism DB, Horwitz EM, Hanlon AL, Pinover WH, Mitra RK, Hanks GE. Late morbidity profiles in prostate cancer patients treated to 79-84 Gy by a simple four-field coplanar beam arrangement. Int J Radiat Oncol Biol Phys. 2003 Jan;55(1):71-7.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term adverse effects

adverse effects Female Middle Aged Aged administration & dosage drug therapy Male therapeutic use Adult pathology 80 and over Aged metabolism effects adverse methods radiotherapy Antineoplastic Combined Chemotherapy Protocols surgery Treatment Outcome analogs & Neoplasm Staging mortality Antineoplastic Agents derivatives radiation effects Ovarian Neoplasms chemically induced prevention & control Apoptosis Biological Tumor Markers therapy Drug Eruptions Patient Education as Topic immunology Survival Rate Pancreatic Neoplasms Conformal Radiotherapy Breast Neoplasms epidemiology DNA Damage Radiotherapy Dosage Neoplasms Carboplatin blood antagonists & inhibitors Protein-Tyrosine Kinases genetics Drug Interactions etiology Deoxycytidine Antineoplastic Antimetabolites Monoclonal Antibodies pharmacokinetics Cultured Cells Paclitaxel Predictive Value of Tests Tetrahydroisoquinolines Colostomy Maximum Tolerated Dose nursing LYMPH-NODES Health Behavior Skin Neoplasms drug Dimerization Survival Analysis CA-19-9 Antigen Genotype RNA Cells Gastrointestinal System Cisplatin Drug Delivery Systems diagnostic use induced Postmenopause Jaw IRRADIATION DNA Repair Polyglutamic Acid Local Neoplasm Recurrence Fallopian Tube Neoplasms Antineoplastic Protocols Sunscreening Agents Attitudes Health Knowledge-Practice Clinical Trials as Topic Gamma Rays use Paronychia Proportional Hazards Models Self-Examination Rosaniline Dyes Hematopoietic Stem Cell Transplantation dosage Safety Prostatic Neoplasms Registries SURGICAL ADJUVANT BREAST Survivors Follow-Up Studies Rh-Hr Blood-Group System Randomized Controlled Trials as Topic Enzyme-Linked Immunosorbent Assay Prospective Studies Urogenital System Diphosphonates therapeutic Feasibility Studies physiopathology CONSERVING THERAPY Neoplastic Gene Expression Regulation Phase III Clinical Trials as Topic Hypercalcemia Drug Therapy statistics & numerical data Graft vs Host Disease Kidney Neoplasms chemically Human Case-Control Studies Histocompatibility Fluorouracil lymph nodes Urticaria Protein Kinase Inhibitors Neutropenia Parenteral Infusions Raloxifene Ethanol combined-modality therapy Alkylation diagnosis Anticarcinogenic Agents Adjuvant Chemotherapy Morbidity PREMENOPAUSAL WOMEN enzymology physiology Drug Dose-Response Relationship Oncologic Nursing AUTOLOGOUS BONE-MARROW Coloring Agents Risk Factors adjuvant Pathologic Neovascularization Hypertension HIGH-RISK RNA Stability Doxorubicin Mitomycin
Last updated on Friday, July 10, 2020